Amgen Aktie News

Despite low relative strength, medical stocks had solid entries in a choppy market.

Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the cheapest quality names using a Magic-Formula-style scoring method.

Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With Extensive Stage Small Cell Lung Cancer That Has Progressed THOUSAND OAKS, Calif. , Nov. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA...

It appears that some investors took a pair of new and bullish pundit takes to heart. One of the pair was a famous stock picker who appears regularly on TV.

Amgen is performing well despite some headwinds, and its pipeline is progressing. Gilead Sciences' strong core franchise and diversification efforts should work wonders.

Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

An analyst bumped his price target higher on the shares. He didn't change his recommendation, however.

New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.